Three-Drug Combination Extends Survival for Patients with Multiple Myeloma

A phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.

Cancer Currents: An NCI Cancer Research Blog